RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more …

Learn more about how RYTELO (imetelstat) may work for lower-risk myelodysplastic syndromes (MDS) patients with transfusion-dependent anemia. See safety information, including …

Rytelo – uniquely positioned to address unmet need in LR- MDS. Rytelois an FDA approved (June 2024), first-in-class telomerase inhibitor to treat lower-risk myelodysplastic syndromes …

Mar 15, 2025 · Rytelo™ (imetelstat) is a first-in-class telomerase inhibitor approved for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) …

Imetelstat, sold under the brand name Rytelo, is an anti-cancer medication used for the treatment of myelodysplastic syndromes with transfusion-dependent anemia. [1] Imetelstat is an …

Drug Identifier results for "Rytelo". Search by imprint, shape, color or drug name.

RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more …

Jul 16, 2024 · Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion …

Rytelo™ (imetelstat) – New orphan drug approval • On June 6, 2024, the FDA announced the approval of Geron’s Rytelo (imetelstat), for the treatment of adult patients with low-to …

Jun 17, 2024 · Imetelstat is a telomerase inhibitor. Telomerase inhibitors work by targeting the telomerase enzyme to stop uncontrolled cell division and do not grow. This is helpful in …